Healthy Skepticism Library item: 1009

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Abelson R.
Asthma Drug Health Risks Are Suspected, Company Says
The New York Times 2003 Jan 24
http://www.nytimes.com/2003/01/24/us/asthma-drug-health-risks-are-suspected.html

Full text:

GlaxoSmithKline said yesterday that Serevent, one of its popular asthma
drugs, might pose a risk of death and serious asthma-related illness in some
patients.
The company said it was halting the study it had been conducting since 1996
to evaluate Serevent’s safety because the study was unlikely to be
conclusive. GlaxoSmithKline said it would work with regulators to design
further studies to address concerns about Serevent’s safety.
While the results of the study were not statistically significant, they
suggested that people who use Serevent, particularly African-Americans,
might be at greater risk for life-threatening attacks or deaths associated
with their asthma. People who use Serevent without also taking inhaled
steroids to control their asthma may also be at increased risk.
The Food and Drug Administration, which issued a statement yesterday about
the study, emphasized that the benefits of Serevent for people with asthma
continued to outweigh the risks based on current information. The agency
said it would meet with GlaxoSmithKline to discuss the findings and was
interested in further evaluating whether certain patients might be at
greater risk for what it described as rare but potentially serious adverse
effects from their use of the drug.
“Patients who require significant treatment should not be afraid of using
Serevent,” said Dr. Lanny Rosenwasser, a professor at the National Jewish
Medical and Research Center and the incoming president of the American
Academy of Allergy Asthma and Immunology.
Previous studies had indicated that Serevent and similar drugs were not
successful in controlling asthma alone, he said.
“You need another controller medicine,” Dr. Rosenwasser said.
GlaxoSmithKline makes another asthma drug, Advair, which has the active drug
in Serevent. But Advair combines Serevent with a type of inhaled steroid
that is recommended by doctors to control the inflammation associated with
asthma.
While Serevent received regulatory approval in 1994, the food and drug
agency said it had received some reports of asthma-related deaths associated
with the drug, which prompted the study. Studies had also raised concerns
about a class of drug known as beta agonists, which includes Serevent. About
26,000 patients participated in the study, which had been intended to enroll
60,000.
Although the preliminary analysis of the study suggested additional risks,
they were not statistically significant because of the small number of
deaths and other serious effects, said Dr. Kate Knobil, a research physician
at GlaxoSmithKline. The company would soon make public the number of these
cases, she said, but was still compiling the information.
The increased risk appears to be driven by the lack of inhaled steroid use,
Dr. Knobil said.
Despite medical recommendations that patients use inhaled steroids or some
other medication, many patients in the study were not being treated with
additional medicine. Less than half, or 47 percent, of the patients used
inhaled steroids. Whether or not a patient was using an inhaled steroid was
determined by that patient’s doctor, not the company.
African-American patients were less likely to be using inhaled steroids and
were more likely to have a more severe case of the disease, which could
partly explain why they were at greater risk for death or other serious
problems. But genetics might also play a role, Dr. Rosenwasser said.
In addition to asking for further studies, the drug agency might require
GlaxoSmithKline to change how it labels the drug or otherwise alert doctors
to its risks.
Analysts played down the significance of the study while acknowledging that
it gives GlaxoSmithKline’s competitors some advantage in promoting their own
drugs to treat asthma.
“It’s a little marketing nudge here and there,” said Todd Lebor, an analyst
with Morningstar Inc. in Chicago.
While the asthma franchise, which includes Advair, is important, Mr. Lebor
said, it is a small part of GlaxoSmithKline’s nearly $30 billion in revenue.
“They don’t have a blockbuster portfolio,” he said.
For the nine months ended Sept. 30, the company sold $574 million in
Serevent, with $327 million coming in the United States. Advair sales
reached $1.7 billion, of which $925 million were in the United States